The subscription status for Concord Biotech Limited’s Initial Public Offering (IPO) has made significant advancements. An impressive total of 24.79 times the subscribed shares have been obtained as of August 8 as the third and final day of the Concord Biotech IPO bidding process came to a close.
Subscription Categories and Figures:
| Subscription Categories | Subscription Oversubscription Ratio |
|---|---|
| Non-Institutional Investors | 16.95 times |
| Retail Investors | 3.64 times |
| Qualified Institutional Buyers | 67.67 times |
Subscription Categories and Numbers:
Across all subscription categories, the IPO had an excellent response. While the Non-Institutional Investor (NII) category experienced a stunning oversubscription of 16.95 times, the Retail Investor category was oversubscribed by 3.64 times. By Tuesday evening at 4:00 PM, Qualified Institutional Buyers (QIBs) had actively participated and had exceeded their quota by 67.67 times of Concord Biotech Ipo.
Minimum Investment and Lot Size:
The minimum investment and lot size for the IPO of Concord Biotech IPO are 20 shares, and the minimum investment amount for retail investors is 14,820.
Grey Market Price of Concorde Biotech IPO
Excellent response to the Concord Biotech IPO, the unofficial market for trading unlisted shares is highly hopeful about this public offering. According to market observers, Concord Biotech IPO shares are currently trading at a higher price of Rs.202 in this unofficial market.
Lead Managers and Registrar:
The book-running lead managers for the Concord Biotech IPO are Kotak Mahindra Capital, Citigroup Global, and Jefferies India. Concorde Biotech IPO’s registrar is Link Intime India Private Limited.
Allotment and Refund:
The book-running lead managers for the Concord Biotech IPO are Kotak Mahindra Capital, Citigroup Global, and Jefferies India. Concorde Biotech IPO’s registrar is Link Intime India Private Limited.
Conclusion:
The High interest shown in Concord Biotech IPO from different investor groups shows the market’s strong curiosity about the company’s services. The grey market price of concord biotech IPO also showing great response today.
More About Concord Biotech IPO
What is the business of Concord Biotech IPO?
Concorde is divided into three business segments: API, Finished Formulation, and Contract Research and Manufacturing.
API Strength: Expertise in Immunopressants, Oncology, Antibacterials, and Antifungals. Specializes in unique, semi-synthetic complex APIs.
Quality Priority: Committed to high-quality standards, complying with global API regulations.
Customer-Centric: Success driven by understanding and meeting customer needs efficiently.